Search results
Results from the WOW.Com Content Network
In combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant ...
Besides its use in medicine, tapinarof is a naturally occurring compound found in bacterial symbionts of nematodes which has antibiotic properties. [2] [3] The medication acts as an aryl hydrocarbon receptor agonist. [1] [4] Tapinarof was approved for medical use in the United States in May 2022.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
The approval of Appili's drug could help ease the metronidazole shortage in the U.S., especially for patients in hospitalized settings and those with severe i Canada's Appili gets US FDA approval ...
The US FDA approved nedosiran based on evidence from a clinical trial which included 29 participants with primary hyperoxaluria type 1. [3] Nedosiran was evaluated in one clinical trial of 29 participants with primary hyperoxaluria type 1 who were nine years of age and older. [ 3 ]
This is a list of common β-lactam antibiotics—both administered drugs and those not in clinical use—organized by structural class. Antibiotics are listed alphabetically within their class or subclass by their nonproprietary name. If an antibiotic is a combination drug, both ingredients will be listed.
Ridinilazole (previously known as SMT19969) is an investigational small molecule antibiotic being evaluated for oral administration to treat Clostridioides difficile infection (CDI). In vitro , it is bactericidal against C. difficile and suppresses bacterial toxin production; the mechanism of action is thought to involve inhibition of cell ...
Cefiderocol may cause serious and life-threatening allergic reactions, severe diarrhea caused by C. difficile and seizures. [9]An increased rate of mortality was observed in people treated with cefiderocol as compared to other antibiotics in a separate clinical trial in critically ill people with multidrug-resistant Gram-negative bacterial infections.